In 2018, burosumab (Crysvita®, Ultragenyx), a recombinant anti-FGF23 monoclonal antibody, was introduced as a treatment for XLH (12), and in 2019 it was approved by the Israeli healthcare basket committee and has become the treatment of choice for pediatric patients with XLH. The gene discussed is FGF23; the disease is X-linked hypophosphatemia.